Get it on Google Play

Compass Therapeutics publishes Phase 2/3 biliary cancer trial results

October 24, 2026 4:15 AM EDT Send to a Friend
Compass Therapeutics, Inc. (NASDAQ: CMPX) announced the publication of results from its Phase 2/3 COMPANION-002 study of tovecimig in the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login